General Information of Drug (ID: DMJ816F)

Drug Name
Sodelglitazar Drug Info
Synonyms
Sodelglitazar; 447406-78-2; UNII-6G973E04VI; 6G973E04VI; GW677954; Sodelglitazar [USAN:INN]; 2-[4-[[[2-[2-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methyl]sulfanyl]-2-methylphenoxy]-2-methylpropanoic acid; 2-(4-(((2-(2-Fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)-2-methylpropanoic acid; Sodelglitazar (USAN); SCHEMBL4822839; CHEMBL2104984; DTXSID90196289; ZUGQWAYOWCBWGM-UHFFFAOYSA-N; ZINC1553281; AN-28238; ACM447406782; FT-0743554; D06647; 406S782; Propanoic ac
Indication
Disease Entry ICD 11 Status REF
Hyperlipidaemia 5C80 Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
9805950
CAS Number
CAS 447406-78-2
TTD Drug ID
DMJ816F

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GFT-505 DM7ZOAE Non-alcoholic steatohepatitis DB92.1 Phase 3 [3]
MBX-8025 DMNTCV4 Obesity 5B81 Phase 2/3 [4]
T3D-959 DMR3245 Alzheimer disease 8A20 Phase 2 [5]
T3D-959 DMR3245 Alzheimer disease 8A20 Phase 2 [6]
KD3010 DMNFDYE Metabolic disorder 5C50-5D2Z Phase 1 [7]
SAR351034 DM15PG9 Dyslipidemia 5C80-5C81 Phase 1 [8]
CER-002 DMLBKZV Dyslipidemia 5C80-5C81 Phase 1 [9]
PMID25416646-Compound-Figure5-C DM17FKL N. A. N. A. Patented [10]
GW-501516 DMPL2KM Type-1 diabetes 5A10 Discontinued in Phase 4 [11]
Indeglitazar DMS56UD Type-2 diabetes 5A11 Discontinued in Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [13]
Pioglitazone DMKJ485 Amyotrophic lateral sclerosis 8B60.0 Approved [14]
Lobeglitazone DMHY3IP Type-2 diabetes 5A11 Approved [15]
Rosiglitazone XR DMT45MU Type-2 diabetes 5A11 Approved [16]
Thiazolidinedione DMC1NBW Alzheimer disease 8A20 Approved [14]
Glitazone DMDN4A1 N. A. N. A. Phase 4 [17]
MURAGLITAZAR DMG3NFZ N. A. N. A. Phase 3 [18]
Rivoglitazone DMBY31K Ocular inflammation 9C61.24 Phase 3 [19]
Balaglitazone DMXBHR6 Type-1 diabetes 5A10 Phase 3 [20]
Ragaglitazar DMFSHEM Type-1 diabetes 5A10 Phase 3 [21]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lobeglitazone DMHY3IP Type-2 diabetes 5A11 Approved [15]
Fenofibrate DMFKXDY Coronary atherosclerosis Approved [17]
Bezafibrate DMZDCS0 Hypercholesterolaemia 5C80.0 Approved [22]
Ciprofibrate DMGC5DB Hyperlipoproteinemia 5C80 Approved [17]
Pemafibrate DMD1VZL Hyperlipidemia 5C80.Z Approved [23]
MURAGLITAZAR DMG3NFZ N. A. N. A. Phase 3 [18]
Ragaglitazar DMFSHEM Type-1 diabetes 5A10 Phase 3 [21]
CS-038 DM67P0F Type-2 diabetes 5A11 Phase 3 [24]
TESAGLITAZAR DMGRBN5 Type-1 diabetes 5A10 Phase 3 [25]
GFT-505 DM7ZOAE Non-alcoholic steatohepatitis DB92.1 Phase 3 [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Peroxisome proliferator-activated receptor alpha (PPARA) TTJ584C PPARA_HUMAN Agonist [2]
Peroxisome proliferator-activated receptor delta (PPARD) TT2JWF6 PPARD_HUMAN Agonist [2]
Peroxisome proliferator-activated receptor gamma (PPAR-gamma) TTZMAO3 PPARG_HUMAN Agonist [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018093)
2 Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar. Protein Pept Lett. 2011 Oct;18(10):1021-7.
3 Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30.
4 ClinicalTrials.gov (NCT00701883) Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol. U. S. National Institute of Health. 2008.
5 Phrma report (2013 Alzheimers disease)
6 T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease. J Alzheimers Dis. 2016;51(1):123-38.
7 Kalypsys nearing completion of phase Ia study of KD3010 for metabolic disorders. Kalypsys. 2007.
8 Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
9 Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol. 2010 May; 30(5): 894-899.
10 PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
11 Lipid effects of peroxisome proliferator-activated receptor- agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.Arterioscler Thromb Vasc Biol.2012 Sep;32(9):2289-94.
12 Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7.
13 Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602.
14 Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7.
15 Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
16 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
17 Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
18 Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
19 A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab. 2011 Sep;13(9):806-13.
20 Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma () agonist.Mini Rev Med Chem.2012 Feb;12(2):87-97.
21 Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.
22 Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in... Mol Pharmacol. 2009 Apr;75(4):782-92.
23 Pemafibrate: First Global Approval. Drugs. 2017 Oct;77(16):1805-1810.
24 Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9.
25 Tesaglitazar, a dual PPAR-/ agonist, hamster carcinogenicity, investigative animal and clinical studies.Toxicol Pathol.2012;40(1):18-32.